| |
|
|
|
Xtalks, Online
2024-03-06
Discover a groundbreaking webinar exploring the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed in the majority of cases of T-ALL but only in a small proportion of normal immune and thymic cells. Thus, an immunotherapy targeted against CCR9 may be able to kill T-ALL cells while preserving critical normal T cells. GenScript has recently demonstrated that chimeric antigen receptor (CAR)-T cells targeting CCR9 were potent in in vitro and murine models of T-ALL and will shortly commence a Phase I clinical trial of anti-CCR9 CAR-T in relapsed or refractory T-ALL.
CCR9 is a complex and challenging target antigen. It is a G-protein coupled receptor with seven transmembrane domains. There is high homology between rodent and human sequences with most differences located intracellularly or at the amino terminus. Thus, developing specific antibodies to CCR9 is difficult, and a previous rat vaccination yielded only a single antibody clone.
Read more...
Join this webinar to gain insights into advancements in T-ALL immunotherapy using CAR-T cells targeting the CCR9 receptor.
Keywords: Immunotherapy, Leukemia, Preclinical, CRO, Oncology, CAR-T, CAR-T Immunotherapy, Preclinical Oncology, Acute Lymphoblastic Leukemia, Pre-Clinical
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Paul Maciocia, Clinical Scientist and Honorary Consultant Haematologist, Cancer Institute, University College London
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-03-06
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|